Candal-Pedreira C; Ruano-Ravina A; Calvo de Juan V; Cobo M; Trigo JM; Carcereny E; Cucurull M; López Castro R; Solís García E; Sánchez-Gastaldo A; Massutí B; Rodríguez-Abreu D; Estival A; Guirado Risueño M; Pamiés Ramón M; Ga "Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study." Erj Open Research 9 (2023): 468-. Aparicio I; Iranzo P; Reyes R; Bote H; Saigi M; Bringas M; Bosch-Barrera J; Corral J; Aparisi F; Ruffinelli JC; Jiménez B; Lage Y; López-Castro R; Majem M; Vázquez S; Artal Á; Rodríguez-Pérez Á; Lázaro-Quintela M; Torres JMS; "Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer." Thrombosis Research 232 (2023): 133-137. Provencio M; Carcereny E; López Castro R; Calvo V; Rodríguez Abreu D; Cobo M; Ortega AL; Bernabé R; Guirado M; Massutí B; Del Barco-Morillo E; Bosch-Barrera J; Camps C; Carroll R; Rault C; Chaib C; Penrod J; Vo L; Ralphs E; D "Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study." Translational Lung Cancer Research 12 (2023): 2113-2128. Provencio M; Estival A; Franco F; López-Vivanco G; Saigí M; Arasanz H; Diz P; Carcereny E; García J; Aguado C; Mosquera J; Iruarrizaga E; Majem M; Bosch-Barrera J; Mielgo-Rubio X; Guirado M; Juan-Vidal Ó; Blasco A; Lucía Gozá "Immunogenicity of COVID-19 vaccines in lung cancer patients." Lung Cancer 184 (2023): 107323-. Provencio M; Nadal E; González-Larriba JL; Martínez-Martí A; Bernabé R; Bosch-Barrera J; Casal-Rubio J; Calvo V; Insa A; Ponce S; Reguart N; de Castro J; Mosquera J; Cobo M; Aguilar A; López Vivanco G; Camps C; López-Castro R "Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer." New England Journal of Medicine 389 (2023): 504-513. Verdura S; Encinar JA; Teixidor E; Segura-Carretero A; Micol V; Cuyàs E; Bosch-Barrera J; Menendez JA "Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors." Cancers 14 (2022): 6101-. Emma Polonio-Alcalá; Rut Porta; Santiago Ruiz-Martínez; Carmen Vasquez-Dongo; Joana Relat; Joaquim Bosch-Barrera; Joaquim Ciurana*; Teresa Puig* "AZ12756122, a novel fatty acid synthase inhibitor, decreases resistance features in EGFR-TKI resistant EGFR-mutated NSCLC cell models." Biomedicine & Pharmacotherapy 156 (2022): -. Moreno V; Roda D; Pikiel J; Trigo JM; Bosch-Barrera J; Drew Y; Kristeleit R; Hiret S; Bajor DL; Cruz P; Beck JT; Ghosh S; Dabrowski C; Antony G; Duan T; Veneris J; Zografos E; Subramanian J "Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial." Clinical Lung Cancer 23 (2022): e415-e427. Serna-Blasco R; Sánchez-Herrero E; Robado de Lope L; Sanz-Moreno S; Rodríguez-Festa A; Ares-Trotta D; Cruz-Bermúdez A; Franco F; Sánchez-Hernández A; Campayo MJ; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch "Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation." Cancers 14 (2022): 4446-. Verdura S; Encinar JA; Fernández-Arroyo S; Joven J; Cuyàs E; Bosch-Barrera J; Menendez JA "Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells." International Journal of Molecular Sciences 23 (2022): 9986-. Provencio M; Cobo M; Rodriguez-Abreu D; Calvo V; Carcereny E; Cantero A; Bernabé R; Benitez G; Castro RL; Massutí B; Del Barco E; García Campelo R; Guirado M; Camps C; Ortega AL; González Larriba JL; Sánchez A; Casal J; Sala "Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics." BMC Cancer 22 (2022): 732-. Riudavets M; Auclin E; Mosteiro M; Dempsey N; Majem M; Lobefaro R; López-Castro R; Bosch-Barrera J; Pilotto S; Escalera E; Tagliamento M; Mosquera J; Zalcman G; Aboubakar-Nana F; Ponce S; Dal Maso A; Spotti M; Mielgo-Rubio X; "Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations." European Journal of Cancer (2022): 142-148. Monteiro C; Miarka L; Perea-García M; Priego N; García-Gómez P; Álvaro-Espinosa L; de Pablos-Aragoneses A; Yebra N; Retana D; Baena P; Fustero-Torre C; Graña-Castro O; Troulé K; Caleiras E; Tezanos P; Muela P; Cintado E; Trej "Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism." Nature Medicine 28 (2022): 752-765. Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M "Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma." Clinical and Translational Oncology 23 (2021): 2560-2567. Ruano-Ravina A; Provencio M; Calvo de Juan V; Carcereny E; Estival A; Rodríguez-Abreu D; Benítez G; López-Castro R; Belver M; Guirado-Risueño M; Guirao-Rubio C; Blasco A; Massutí B; Ortega AL; Cobo M; Mosquera-Martínez J; Agu "Are there differences by sex in lung cancer characteristics at diagnosis? -a nationwide study." Translational Lung Cancer Research 10 (2021): 3902-3911. Emma Polonio-Alcalá; Marc Rabionet; Santiago Ruiz-Martínez; Sònia Palomeras; Rut Porta; Carmen Vásquez-Dongo; Joaquim Bosch-Barrera; Teresa Puig*; Joaquim Ciurana*. "Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma." Cancers 13 (2021): 5320-. Niksic M; Redondo-Sanchez D; Chang YL; Rodriguez-Barranco M; Exposito-Hernandez J; Marcos-Gragera R; Oliva-Poch E; Bosch-Barrera J; Sanchez MJ; Luque-Fernandez MA "The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study." BMC Cancer 21 (2021): 1048-. Garrido P; Paz-Ares L; Majem M; Morán T; Trigo JM; Bosch-Barrera J; Garcίa-Campelo R; González-Larriba JL; Sánchez-Torres JM; Isla D; Viñolas N; Camps C; Insa A; Juan Ó; Massuti B; Paredes A; Artal Á; López-Brea M; Palac "LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology." Cancer Medicine 10 (2021): 5878-5888. Bosch-Barrera J; Verdura S; Ruffinelli JC; Carcereny E; Sais E; Cuyàs E; Palmero R; Lopez-Bonet E; Hernández-Martínez A; Oliveras G; Buxó M; Izquierdo A; Morán T; Nadal E; Menendez JA "Silibinin suppresses tumor cell-intrinsic resistance to Nintedanib and enhances its clinical cctivity in Lung Cancer." Cancers 13 (2021): 4168-. Gutiérrez L; Royuela A; Carcereny E; López-Castro R; Rodríguez-Abreu D; Massuti B; González-Larriba JL; García-Campelo R; Bosch-Barrera J; Guirado M; Camps C; Dómine M; Bernabé R; Casal J; Oramas J; Ortega AL; Sala MA; Padill "Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data." BMC Cancer 21 (2021): 977-. Jiménez-Labaig P; Pacheco-Barcia V; Cebrià A; Gálvez F; Obispo B; Páez D; Quílez A; Quintanar T; Ramchandani A; Remon J; Rogado J; Sánchez DA; Sánchez-Cánovas M; Sanz-García E; Sesma A; Tarazona N; Cotés A; González E; Bosch- "Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM)." Esmo Open 6 (2021): 100215-. Grossi F; Jaśkiewicz P; Ferreira M; Czyżewicz G; Kowalski D; Ciuffreda L; Garcia-Gomez R; Caruso S; Bosch-Barrera J; Gautier S; Ta Thanh Minh C; Henriet S; de Castro G Jr "Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03)." Therapeutic Advances In Medical Oncology (2021): 175883592110229-. Muñoz-Guardiola P; Casas J; Megías-Roda E; Solé S; Perez-Montoyo H; Yeste-Velasco M; Erazo T; Diéguez-Martínez N; Espinosa-Gil S; Muñoz-Pinedo C; Yoldi G; Abad JL; Segura MF; Moran T; Romeo M; Bosch-Barrera J; Oaknin A; Alfón "The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells." Autophagy 17 (2021): 1349-1366. Franco F; Carcereny E; Guirado M; Ortega AL; López-Castro R; Rodríguez-Abreu D; García-Campelo R; Del Barco E; Juan O; Aparisi F; González-Larriba JL; Domine M; Trigo JM; Cobo M; Cerezo S; Calzas J; Massutí B; Bosch-Barrera J "Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry." PLoS One 16 (2021): e0251761-. Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Cha "Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment." European Journal of Cancer (2021): 61-72. Camerini A; Morabito A; Montanino A; Bernabé R; Grossi F; Ramlau R; Ciuleanu TE; Ceresoli GL; Pasello G; de Marinis F; Bosch-Barrera J; Laundreau P; Gautier S; Ta Thanh Minh C; Kowalski D "Metronomic oral vinorelbine in previously untreated advanced non-small-cell lung cancer patients unfit for platinum-based chemotherapy: results of the randomized phase II Tempo Lung trial." Esmo Open 6 (2021): 100051-. Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; C "Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group." BMC Cancer 21 (2021): 230-. Romero A; Jantus-Lewintre E; García-Peláez B; Royuela A; Insa A; Cruz P; Collazo A; Pérez Altozano J; Vidal OJ; Diz P; Cobo M; Hernández B; Vázquez Estevez S; Benítez G; Guirado M; Majem M; Bernabé R; Ortega AL; Blasco A; Bos "Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing: results of the RING observational trial." Molecular Oncology 15 (2021): 43-56. Garcia-Campelo R; Arrieta O; Massuti B; Rodriguez-Abreu D; Granados ALO; Majem M; Vicente D; Lianes P; Bosch-Barrera J; Insa A; Dómine M; Reguart N; Guirado M; Sala MÁ; Vázquez-Estevez S; Caro RB; Drozdowskyj A; Verdú A; Kara "Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)." Lung Cancer (2020): 62-69. Cuyàs E; Gumuzio J; Lozano-Sánchez J; Segura-Carretero A; Verdura S; Bosch-Barrera J; Martin-Castillo B; Nonell-Canals A; Llebaria A; Cabello S; Serra C; Sanchez-Martinez M; Martin ÁG; Menendez JA "Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity." Aging 12 (2020): 21057-21075. Barquín M; Calvo V; García-García F; Nuñez B; Sánchez-Herrero E; Serna-Blasco R; Auglytė M; Carcereny E; Rodriguez-Abreu D; López Castro R; Guirado M; Camps C; Bosch-Barrera J; Massuti B; Ortega AL; Del Barco E; Gonzalez "Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation." Cancer Epidemiology (2020): 101737-. Bosch-Barrera J; Martin-Castillo B; Buxó M; Brunet J; Encinar JA; Menendez JA "Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patient." Journal of Clinical Medicine 9 (2020): 1770-. Cuyàs E; Gumuzio J; Verdura S; Brunet J; Bosch-Barrera J; Martin-Castillo B; Alarcón T; Encinar JA; Martin ÁG; Menendez JA "The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes." Aging 12 (2020): 4794-4814. Verdura S; Cuyas E; Cortada E; Brunet J; Lopez-Bonet E; Martin-Castillo B; Bosch-Barrera J; Encinar JA; Menendez JA "Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity." Aging 12 (2020): 8-34. Cuyàs E; Verdura S; Micol V; Joven J; Bosch-Barrera J; Encinar JA; Menendez JA "Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation." Food and Chemical Toxicology 132 (2019): -. Cuyàs E; Castillo D; Llorach-Parés L; Lozano-Sánchez J; Verdura S; Nonell-Canals A; Brunet J; Bosch-Barrera J; Joven J; Valdés R; Sanchez-Martinez M; Segura-Carretero A; Menendez JA "Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets." Food and Chemical Toxicology 131 (2019): -. Provencio M; Carcereny E; Rodríguez-Abreu D; López-Castro R; Guirado M; Camps C; Bosch-Barrera J; García-Campelo R; Ortega-Granados AL; González-Larriba JL; Casal-Rubio J; Domine M; Massutí B; Sala MÁ; Bernabé R; Oramas J; De "Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)." Translational Lung Cancer Research 8 (2019): 461-475. Cuyàs E; Gumuzio J; Lozano-Sánchez J; Carreras D; Verdura S; Llorach-Parés L; Sanchez-Martinez M; Selga E; Pérez GJ; Scornik FS; Brugada R; Bosch-Barrera J; Segura-Carretero A; Martin ÁG; Encinar JA; Menendez JA. "Extra virgin olive oil contains a phenolic inhibitor of the histone demethylase LSD1/KDM1A." Nutrients 11 (2019): 1656-. Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M "Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns." Clinical Lung Cancer (2019): -. Pérez-Sánchez A; Cuyàs E; Ruiz-Torres V; Agulló-Chazarra L; Verdura S; González-Álvarez I; Bermejo M; Joven J; Micol V; Bosch-Barrera J; Menendez JA "Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers." International Journal of Molecular Sciences 20 (2019): 1606-. Cuyàs E; Verdura S; Lozano-Sánchez J; Viciano I; Llorach-Parés L; Nonell-Canals A; Bosch-Barrera J; Brunet J; Segura-Carretero A; Sanchez-Martinez M; Encinar JA; Menendez JA "The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase." Food and Chemical Toxicology 128 (2019): 35-45. Elez E; Quintanar T; Bosch-Barrera J; Corral J; Lainez N; Moreno V; Rodriguez CA; Gonzalez-Flores E; Cervantes A "The Medical Oncology resident mentor: situation and workload." Clinical and Translational Oncology 21 (2019): 304-313. Verdura S; Cuyàs E; Lozano-Sánchez J; Bastidas-Velez C; Llorach-Parés L; Fernández-Arroyo S; Hernández-Aguilera A; Joven J; Nonell-Canals A; Bosch-Barrera J; Martin-Castillo B; Vellon L; Sanchez-Martinez M; Segura-Carretero A "An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors." Carcinogenesis 40 (2019): 27-40. Cuyàs E; Verdura S; Llorach-Parés L; Fernández-Arroyo S; Joven J; Martin-Castillo B; Bosch-Barrera J; Brunet J; Nonell-Canals A; Sanchez-Martinez M; Menendez JA "Metformin is a direct SIRT1-activating compound: computational modeling and experimental validation." Frontiers In Endocrinology 9 (2018): -. Teixidor E; Sais E; Vásquez CA; Carbajal W; Hernández A; Sánchez G; Izquierdo A; Verdura S; Menéndez JA; Bosch-Barrera J "Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma." Oncotarget 9 (2018): 33043-33049. Priego N; Zhu L; Monteiro C; Mulders M; Wasilewski D; Bindeman W; Doglio L; Martínez L; Martínez-Saez E; Ramón Y Cajal S; Megías D; Hernández-Encinas E; Blanco-Aparicio C; Martínez L; Zarzuela E; Muñoz J; Fustero-Torre C; Piñ "STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis." Nature Medicine 24 (2018): 1024-1035. Morán T; Felip E; Bosch-Barrera J; de Aguirre I; Ramirez JL; Mesia C; Carcereny E; Roa D; Sais E; García Y; Blanco R; Sanchez S; Villacorta CR; Queralt C; Velarde JM; Rosell R "Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer." Oncotarget 9 (2018): 27074-27086. Verdura S; Cuyàs E; Llorach-Parés L; Pérez-Sánchez A; Micol V; Nonell-Canals A; Joven J; Valiente M; Sánchez-Martínez M; Bosch-Barrera J; Menendez JA "Silibinin is a direct inhibitor of STAT3." Food and Chemical Toxicology 116 (2018): 161-172. Cuyàs E; Verdura S; Fernández-Arroyo S; Bosch-Barrera J; Martin-Castillo B; Joven J; Menendez JA "Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity." Oncotarget 8 (2017): 99223-99236. Bosch-Barrera J; Queralt B; Menendez JA "Targeting STAT3 with silibinin to improve cancer therapeutics." Cancer Treatment Reviews (2017): 61-69. Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA. "EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells." Oncology Reports 38 (2017): 263-270. Cuyàs E; Martin-Castillo B; Bosch-Barrera J; Menendez JA "Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.." Cell Cycle 16 (2017): 1022-1028. Elisabet Cuyàs; Bruna Corominas-Faja; María Muñoz-San Martín; Begoña Martin-Castillo; Ruth Lupu; Joan Brunet; Joaquim Bosch-Barrera; Javier A. Menendez "BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancerinitiating cells." Oncotarget 8 (2017): 35019-35032. Moran T; Palmero R; Provencio M; Insa A; Majem M; Reguart N; Bosch-Barrera J; Isla D; Costa EC; Lee C; Puig M; Kraemer S; Schnell D; Rosell R "A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.." Lung Cancer (2017): -. Wehler T; Thomas M; Schumann C; Bosch-Barrera J, Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L "A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.." Lung Cancer (2017): 212-216. Sais E; Menéndez JA; Bosch-Barrera J "The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?." Translational Cancer Research 6 (2017): S201-S204. Ferreira-Padilla G; Ferrández-Antón T; Lolas-Stepke F; Almeida-Cabrera R; Brunet J; Bosch-Barrera J "Ethics competences in the undergraduate medical education curriculum: the Spanish experience.." CMJ: Croatian Medical Journal 57 (2016): 493-503. Cuyàs E; Pérez-Sánchez A; Micol V; Menendez JA; Bosch-Barrera J. "STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer.." Cell Cycle (2016): -. Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; De Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA. "Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer." Oncotarget 7 (2016): 82185-82199. de Kock L; Bah I; Brunet J; Druker H; Astigarraga I; Bosch-Barrera J; Soglio DB; Nguyen VH; Malkin D; Priest JR; Foulkes WD. "Somatic DICER1 mutations in adult-onset pulmonary blastoma." European Respiratory Journal (2016): -. Bosch-Barrera J; Sais E; Cañete N; Marruecos J; Cuyàs E; Izquierdo A; Porta R; Haro M; Brunet J; Pedraza S; Menendez JA "Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin." Oncotarget 7 (2016): 32006-32014. Fernández-Arroyo S; Cuyàs E; Bosch-Barrera J; Alarcón T; Joven J; Menendez JA "Activation of the methylation cycle in cells reprogrammed into a stem cell-like state.." Oncoscience 2 (2016): 958-967. Karachaliou N; Codony-Servat J; Teixidó C; Pilotto S; Drozdowskyj A; Codony-Servat C; Giménez-Capitán A; Molina-Vila MA; Bertrán-Alamillo J; Gervais R; Massuti B; Morán T; Majem M; Felip E; Carcereny E; García-Campelo R; Vite "BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.." Scientific Reports (2015): -. Bosch-Barrera J; Holguin F; Baldó X; Rubio M; Porta R; Fuentes R; Teixidó C; Ramirez JL; Ferran N; Sebastián F; Rosell R "Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression." Anticancer Research 35 (2015): 4871-4875. Cuyàs, E; Fernández-Arroyo, S; Corominas-Faja, B; Rodríguez-Gallego, E; Bosch-Barrera, J; Martin-Castillo, B; De Llorens, R; Joven, J; Menendez, J.A "Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype." Oncotarget 6 (2015): 12279-12296. Cuyàs, E; Martin-Castillo, B; Corominas-Faja, B; Massaguer, A; Bosch-Barrera, J; Menendez, J.A. "Anti-protozoal and anti-bacterial Antibiotics that inhibit protein synthesis kill Cancer subtypes enriched for stem cell-like properties." Cell Cycle 14 (2015): 3527-3532. Bosch-Barrera J; Briceño García HC; Capella D; De Castro Vila C; Farrés R; Quintanas A; Ramis J; Roca R; Brunet J "Teaching Bioethics to Students of Medicine with Problem-Based Learning (PBL)." Cuadernos de Bioética 26 (2015): 303-309. Bosch-Barrera J; Menendez JA. "Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy.." Cancer Treatment Reviews (2015): -. Sauri T; Izquierdo À; Ramió-Torrentà L; Sanchez-Montañez À; Bosch-Barrera J; Porta R "Paraneoplastic Limbic Encephalitis in a Male with Squamous CellCarcinoma of the Lung." Journal Of Clinical Neurology 11 (2015): 87-91. Vidal J; Clavé S; de Muga S; González I; Pijuan L; Gimeno J; Remón J; Reguart N; Viñolas N; Gironés R; Bernet L;, Majem M; Bosch-Barrera J; Porta R; Alonso N; Palmero R; Taus A; Albanell J; Espinet B; Salido M; Arriola E "Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients." Journal of Thoracic Oncology 9 (2014): 1816-1820. Bosch-Barrera J; Sais E; Lorencio C; Porta R; Izquierdo A; Menéndez JA; Brunet J; Sirvent JM; Rosell R "Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma." Lung Cancer 86 (2014): 102-104. Corominas-Faja, B; Cuyàs, E; Gumuzio, J; Bosch-Barrera, J; Leis, O; Martin, A.G; Menendez, J.A "Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells." Oncotarget 5 (2014): 8306-8316. Bosch-Barrera J; Corominas-Faja B; Cuyàs E; Martin-Castillo B; Brunet J; Menendez JA "Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient." Anticancer Research 34 (2014): 4323-4327. Javier A. Menendez; Rosa Quirantes-Piné; Esther Rodríguez-Gallego; Sílvia Cufí; Bruna Corominas-Faja; Elisabet Cuyàs; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Antonio Segura-Carretero; Jorge Joven "Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment." Oncotarget 5 (2014): 2344-2348. Bruna Corominas-Faja; Cristina Oliveras-Ferraros; Elisabet Cuyàs; Antonio Segura-Carretero; Jorge Joven; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol; Joaquim Bosch-Barrera; Menendez JA "Stem cell-like ALDHbright cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.." Cell Cycle (2013): -. Alejandro Vazquez-Martin; Sílvia Cufí; Cristina Oliveras-Ferraros; Violeta Zenobia Torres-Garcia; Bruna Corominas-Faja; Elisabet Cuyàs; Rosa Bonavia; Joana Visa; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Vicente Micol "IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations.." Scientific Reports (2013): -. Sílvia Cufí; Rosa Bonavia; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Bruna Corominas-Faja; Elisabet Cuyàs; Begoña Martin-Castillo; Enrique Barrajón-Catalán; Joana Visa; Antonio Segura-Carretero; Jorge Joven; Joaqu "Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo.." Scientific Reports (2013): -. Sílvia Cufí, Rosa Bonavia, Alejandro Vazquez-Martin, Bruna Corominas-Faja, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Begoña Martin-Castillo, Enrique Barrajón-Catalán, Joana Visa, Antonio Segura-Carretero, Joaquim Bosch-Barr "Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.." Food and Chemical Toxicology (2013): -. Castañon E; Bosch-Barrera J; López I; Collado V; Moreno M; López-Picazo JM; Arbea L; Lozano MD; Calvo A; Gil-Bazo I. "Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy.." Journal Of Translational Medicine 11 (2013): -. Bosch-Barrera J; García-Franco C; Guillén-Grima F; Moreno-Jiménez M; López-Picazo JM; Gúrpide A; Pérez-Gracia JL; Aristu J; Torre W; García-Foncillas J; Gil-Bazo I. "The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience.." Clinical and Translational Oncology 14 (2012): 835-841. Oliveras-Ferraros C; Cufí S; Queralt B; Vazquez-Martin A; Martin-Castillo B; de Llorens R; Bosch-Barrera J; Brunet J; Menendez JA "Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells.." British Journal of Cancer 106 (2012): 1406-1414. Sílvia Cufí; Bruna Corominas-Faja; Alejandro Vazquez-Martin; Cristina Oliveras-Ferraros; Joan Dorca; Joaquim Bosch-Barrera; Begoña Martin-Castillo; Javier A. Menendez "Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts." Oncotarget 4 (2012): 395-398. Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Quirantes R; Segura-Carretero A; Micol V; Joven J; Bosch-Barrera J; Del Barco S; Martin-Castillo B; Vellon L; Menendez JA. "Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205." Cell Cycle 11 (2012): 1235-1246. Oliveras-Ferraros C; Cufí S; Vazquez-Martin A; Menendez OJ; Bosch-Barrera J; Martin-Castillo B; Joven J; Menendez JA "Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation.." Cell Cycle 11 (2012): 865-870. Cristina Oliveras-Ferraros; Anna Massaguer Vall-Llovera; Alejandro Vazquez-Martin; Dolors Carrion Salip; Bernardo Queralt; Silvia Cufí; Begoña Martin-Castillo; Joaquim Bosch-Barrera; Joan Brunet; Rafael De Llorens; Javier A. "Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment.." Oncology Reports 27 (2012): 1887-1892. Bosch-Barrera J; Quer N; Brunet J "Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective.." Clinical Lung Cancer 12 (2011): 335-340. Bosch-Barrera J; Urdiroz J; Centeno C "Visual hallucinations and unusual pain related to hypomagnesemia in an advanced cancer patient." Anales del Sistema Sanitario de Navarra 33 (2010): 319-322. Bosch-Barrera J; Espinós J. "Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report.." International Archives of Medicine 3 (2010): 1-3. Bosch-Barrera J; Espinós J; Gómez-Ibáñez A; Gállego Pérez-Larraya J; Iriarte J "Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone.." Clinical and Translational Oncology 11 (2009): 765-767. Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I "Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.." Onkologie 32 (2009): 580-584. Bosch-Barrera J; Arbea L; García-Velloso MJ; Gil-Bazo I; García-Foncillas J; Panizo C "Primary bone lymphoma of the mandible and thyroid incidentaloma identified by FDG PET/CT: a case report.." Cases Journal 2 (2009): 1-5. Bosch-Barrera J; Montero A; López-Picazo JM; García-Foncillas J; Ferrer M; Yuste JR; Gil-Bazo I. "Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer." Lung Cancer 64 (2009): 124-126.
Bosch-Barrera J; Roqué A; Teixidor E; Carmona-Garcia MC; Arbusà A; Brunet J; Martin-Castillo B; Cuyàs E; Verdura S; Menendez JA "Clinical management of COVID-19 in cancer patients with the STAT3 inhibitor silibinin." Pharmaceuticals 15 (2021): 19-.
Verdura S; Cuyàs E; Ruiz-Torres V; Micol V; Joven J; Bosch-Barrera J; Menendez JA "Lung Cancer Management with Silibinin: A Historical and Translational Perspective." Pharmaceuticals 14 (2021): 559-. Nadal E; Bosch-Barrera J; Cedrés S; Coves J; García-Campelo R; Guirado M; López-Castro R; Ortega AL; Vicente D; de Castro-Carpeño J "SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)." Clinical and Translational Oncology 23 (2021): 980-987. Jablonska PA; Bosch-Barrera J; Serrano D; Valiente M; Calvo A; Aristu J "Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer." Cancers 13 (2021): 2141-. Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E "Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic." Cancer Treatment Reviews (2020): 102067-. Cuyàs E; Verdura S; Martin-Castillo B; Alarcón T; Lupu R; Bosch-Barrera J; Menendez JA "Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy." Cancers 12 (2020): 1757-. Isla D; Afonso R; Bosch-Barrera J; Martínez N. "Zoledronic acid in lung cancer with bone metastases: a review.." Expert Review Of Anticancer Therapy 13 (2013): 421-426. Del Barco S; Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Bosch-Barrera J; Joven J; Martin-Castillo B; Menendez JA. "Metformin: multi-faceted protection against cancer.." Oncotarget 2 (2011): 896-917. Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C "Direct antitumour activity of zoledronic acid: preclinical and clinical data." Clinical and Translational Oncology 13 (2011): 148-155. Bosch-Barrera J "Ethical dilemmas in the medical practice in 2010: reflexions around the results of a survey to 10,000 physicians." Cuadernos de Bioética 22 (2011): 113-118. Bosch-Barrera J; Hernández A; Abella LE "Insulin and insulin-like growth factor pathway, a new targeted therapy in oncology." Anales del Sistema Sanitario de Navarra 32 (2009): 413-421. Bosch Barrera, J.; López-Picazo González, JM.; García-Foncillas López, J.; Prósper Cardoso, F. "Stem cells and cancer: elucidating the origin of the cancer stem cell." Rev Med Univ Navarra 51 (2007): 14-17.
Bosch-Barrera J; Oliva E; Sais E; Vásquez CA; Roselló A; Menéndez JA "Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer." Anti-Cancer Drugs 30 (2019): 1067-1070. Teixidor E; Bosch-Barrera J "The dark side of immunotherapy: challenges facing the new hope in cancer treatment." Annals Of Translational Medicine (2019): -. López Brunsó M; Toro Blanch C; Sais Girona E; Roa García D; Hernández Martínez A; Izquierdo Font A; Guerra Prió S; Mas Pueyo HG; Bosch-Barrera J "Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer." Anti-Cancer Drugs 29 (2018): 380-383. Bosch-Barrera J; Gil-Bazo I. "Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany." Lung Cancer 71 (2011): 244-244.